Lancashire and South Cumbria
Formulary
Formulary
5 Infections
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
This chapter of the formulary is under development, please use local/national antimicrobial guidelines to support prescribing choices.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
The formulary development team can be contacted here: mlcsu.lscformulary@nhs.net
Prescribers must follow the relevant local and national guidance when treating an infection. Some anti-infectives require approval from the local Trust microbiology team for use, consult local guidance for further information.Not all anti-infectives listed in this chapter will be available in all localities; availability will be guided by local need and resistance patterns. |
05-03-01 Non-nucleoside reverse transcriptase inhibitors
Specialist prescribing only| Etravirine Intelence® |
|
Formulary
|
Tablets 100mg, 200mg |
 MHRA: Etravirine: reports of severe hypersensitivity reactions |
|
Links
- Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older) - Supply Disruption
Blackpool Teaching Hospitals: Antimicrobial Formulary- British Association for Sexual Health and HIV
- British HIV Association: Current Guidelines
- Central Lancashire/LSCFT/Morecambe Bay Primary Care: NICE Summary of antimicrobial prescribing guidance - managing common infections
- Clinical commissioning policy statement: Stribild for the treatment of HIV-1 infection in adults
- East Lancashire Primary Care: Antimicrobial guide primary care
- East Lancashire Secondary Care: Antimicrobial guide secondary care
- HIV Drug Interactions
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (App store)
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (Google)
- LSCMMG: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab
- LSCMMG: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab
- LSCMMG: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab
- MHRA Drug Safety Update July 2018: Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
- MHRA Drug Safety Update Oct 2018: Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels
- MHRA Drug Safety Update Oct 2018: Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels
- MHRA Drug Safety Update Oct 2020: Dolutegravir (Tivicay, Triumeq, Juluca): updated advice on increased risk of neural tube defects
- MHRA Drug Safety Update Oct 2020: Dolutegravir (Tivicay, Triumeq, Juluca): updated advice on increased risk of neural tube defects
- MHRA Drug Safety Update: Abacavir: risk of myocardial infarction—update from epidemiological studies
- MHRA Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA Drug Safety Update: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA Drug Safety Update: Etravirine: reports of severe hypersensitivity reactions
- MHRA Drug Safety Update: Saquinavir: update on potential risk of arrhythmia
- MHRA DSU April 2019: Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
- MHRA safety information on adverse effects April 2011
- MHRA: Abacavir: risk of myocardial infarction—update from epidemiological studies
- MHRA: Abacavir: risk of myocardial infarction—update from epidemiological studies
- MHRA: Abacavir: risk of myocardial infarction—update from epidemiological studies
- MHRA: Abacavir: risk of myocardial infarction—update from epidemiological studies
- MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA: Cobicistat, ritonavir and coadministration with a steroid: risk of systemic corticosteroid adverse effects
- MHRA: COVID-19 antivirals: reporting to the UK COVID-19 Antivirals Pregnancy Registry
- MHRA: COVID-19 antivirals: reporting to the UK COVID-19 Antivirals Pregnancy Registry
- MHRA: Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
- MHRA: Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
- MHRA: Darunavir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
- MHRA: Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects
- MHRA: Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects
- MHRA: Dolutegravir (Tivicay▼, Triumeq▼, Juluca▼): updated advice on increased risk of neural tube defects
- MHRA: Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
- MHRA: Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
- MHRA: Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1
- MHRA: Etravirine: reports of severe hypersensitivity reactions
- MHRA: Nirmatrelvir, ritonavir (Paxlovid▼): be alert to the risk of drug interactions with ritonavir
- MHRA: Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels
- MHRA: Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels
- MHRA: Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation
- NHS England Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and older)
- NICE CG165: Hepatitis B (chronic) - incorporates TA173
- NICE CG165: Hepatitis B (chronic): diagnosis and management
- NICE CG165: Hepatitis B (chronic): diagnosis and management
- NICE ES27: COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19
- NICE NG120: Cough (acute): antimicrobial prescribing
- NICE NG125: Surgical site infections: prevention and treatment
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG191 COVID-19 rapid guideline: managing COVID-19
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG240: Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management
- NICE NG51: Sepsis: recognition, diagnosis and early management
- NICE NG78: Cystic fibrosis: diagnosis and management
- NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
- NICE TA173: Tenofovir disoproxil for the treatment of chronic hepatitis B
- NICE TA757: Cabotegravir with rilpivirine for treating HIV-1
- NICE TA757: Cabotegravir with rilpivirine for treating HIV-1
- NICE TA757:Cabotegravir with rilpivirine for treating HIV-1
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA900:Tixagevimab plus cilgavimab for preventing COVID-19
- NICE TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19
- Publication of an interim clinical commissioning policy: Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older).
- University Hospitals of Morecambe Bay: Antimicrobial guide secondary care
- West Lancashire Primary Care: Pan Mersey antimicrobial guide
- WHO: AWaRe classification of antibiotics for evaluation and monitoring of use, 2023